Proton beam radiotherapy for uveal melanoma: Results of Curie Institut-Orsay Proton Therapy Center (ICPO)

Journal Article · Sat Jul 01 00:00:00 EDT 2006 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2006.01.020· OSTI ID:20842910

Dendale, Remi ^[1]; Lumbroso-Le Rouic, Livia ^[2]; Noel, Georges ^[3]; Feuvret, Loic ^[3]; Levy, Christine ^[2]; Delacroix, Sabine ^[3]; Meyer, Anne ^[4]; Nauraye, Catherine ^[3]; Mazal, Alejandro ^[5]; Mammar, Hamid ^[5]; Garcia, Paul ^[3]; D'Hermies, Francois ^[4]; Frau, Eric ^[6]; Plancher, Corine ^[7]; Asselain, Bernard ^[7]; Schlienger, Pierre ^[5]; Mazeron, Jean Jacques ^[3]; Desjardins, Laurence ^[2]

---

1. Department of Radiation Oncology, Curie Institut, Paris (France) and Curie Institut-Orsay Protontherapie Center, Orsay (France)
2. Department of Ophthalmology, Curie Institut, Paris (France)
3. Curie Institut-Orsay Protontherapie Center, Orsay (France)
4. Department of Ophthalmology, Hotel Dieu Hospital, Paris (France)
5. Department of Radiation Oncology, Curie Institut, Paris (France)
6. Department of Ophthalmology, Le Kremlin Bicetre Hospital, Le Kremlin Bicetre (France)
7. Department of Biostatistics, Curie Institut, Paris (France)

Purpose: This study reports the results of proton beam radiotherapy based on a retrospective series of patients treated for uveal melanoma at the Orsay Center. Methods and Materials: Between September 1991 and September 2001, 1,406 patients with uveal melanoma were treated by proton beam radiotherapy. A total dose of 60 cobalt Gray equivalent (CGE) was delivered in 4 fractions on 4 days. Survival rates were determined using Kaplan-Meier estimates. Prognostic factors were determined by multivariate analysis using the Cox model. Results: The median follow-up was 73 months (range, 24-142 months). The 5-year overall survival and metastasis-free survival rates were 79% and 80.6%, respectively. The 5-year local control rate was 96%. The 5-year enucleation for complications rate was 7.7%. Independent prognostic factors for overall survival were age (p < 0.0001), gender (p < 0.0003), tumor site (p < 0.0001), tumor thickness (p = 0.02), tumor diameter (p < 0.0001), and retinal area receiving at least 30 CGE (p = 0.003). Independent prognostic factors for metastasis-free survival were age (p = 0.0042), retinal detachment (p = 0.01), tumor site (p < 0.0001), tumor volume (p < 0.0001), local recurrence (p < 0.0001), and retinal area receiving at least 30 CGE (p = 0.002). Independent prognostic factors for local control were tumor diameter (p = 0.003) and macular area receiving at least 30 CGE (p = 0.01). Independent prognostic factors for enucleation for complications were tumor thickness (p < 0.0001) and lens volume receiving at least 30 CGE (p = 0.0002). Conclusion: This retrospective study confirms that proton beam radiotherapy ensures an excellent local control rate. Further clinical studies are required to decrease the incidence of postirradiation ocular complications.

• OSTI ID: 20842910
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 65, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2006.01.020; PII: S0360-3016(06)00162-3; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
COBALT 60
MELANOMAS
METASTASES
PATIENTS
PROTON BEAMS
RADIATION DOSES
RADIOTHERAPY
THICKNESS